Abstracts tagged "Cardiovascular"

Abstract Number: 2221 • ACR Convergence 2025
Racial Differences in Cardiovascular Events and Adverse Pregnancy Outcomes Among Pregnant Individuals With Systemic Lupus Erythematosus
Rashmi Dhital¹, Rebecca Baer² and Christina Chambers³, ¹Vanderbilt University Medical Center, Brentwood, TN, ²University of California San Diego, San Diego, CA, ³University of California, San Diego, La Jolla, CA
Background/Purpose: Pregnant individuals with systemic lupus erythematosus (SLE) face an increased risk of cardiovascular events (CVEs) as well as adverse pregnancy outcomes (APOs). While racial…
Abstract Number: 1716 • ACR Convergence 2025
The frequency and impact of cardiovascular disease in systemic lupus erythematosus: a Nationwide, matched case-control study.
Jessica Fairley¹, Laura Ross¹, Elizabeth Paratz², Penelope McKelvie³, Simin Daneshvar³, Shereen Oon⁴, Dylan Hansen³, Wendy Stevens¹, Andre La Gerche² and Mandana Nikpour⁵, ¹The University of Melbourne, Melbourne, Victoria, Australia, ²St Vincent's Institute of Medical Research, Melbourne, Victoria, Australia, ³St Vincent's Hospital Melbourne, Melbourne, Victoria, Australia, ⁴St Vincent’s Hospital Melbourne, Melbourne, Victoria, Australia, ⁵University of Sydney School of Public Health and Department of Rheumatology, Royal Prince Alfred Hospital, Sydney, Victoria, Australia
Background/Purpose: Cardiovascular disease is the leading cause of death in systemic lupus erythematosus (SLE).1 Whilst histopathology remains the gold standard for establishing the pathogenesis of…
Abstract Number: 1334 • ACR Convergence 2025
Cardiac Biomarkers and Prediction of Major Cardiovascular Events in Rheumatoid Arthritis: Results from the ESPOIR Cohort
manon lesturgie¹, Fiona Oudart¹, Anne Cauvet², Virginie Gonzalez², Bruno Fautrel³, Arnaud Constantin⁴, Nathalie Rincheval⁵, Yannick Allanore⁶ and Jérôme Avouac⁷, ¹INSERM U¹⁰¹⁶, Paris, France, ²INSERMU¹⁰¹⁶, Paris, France, ³Sorbonne Université - APHP, Department of Rheumatology, Hôpital Pitié-Salpêtrière, Inserm UMRS ¹¹³⁶-⁵, PARIS, France, Paris, France, ⁴Hôpital Pierre-Paul Riquet, CHU Purpan, Toulouse, France, ⁵Institut de Recherche Clinique EA²⁴¹⁵, Université de Montpellier, Département de Statistiques, Montpellier, France, ⁶Université Paris Cité, Paris, France, ⁷Hôpital Cochin, AP-HP Centre - Université Paris Cité, Paris, France
Background/Purpose: Patients with rheumatoid arthritis (RA) experience premature mortality, largely due to cardiovascular (CV) disease. The increased CV risk is due to both the underlying…
Abstract Number: 0671 • ACR Convergence 2025
The Gut-Heart Axis in Systemic Sclerosis: Evidence from the GENISOS cohort
Francesca Romana Di Ciommo¹, Ashish Balar², Subhash Kulkarni³, Aidan K Strother², Michael Hughes⁴, Brian Skaug⁵, Maureen Mayes⁶, Shervin Assassi⁷, Ali Y Ayla² and Zsuzsanna McMahan⁸, ¹La Sapienza University of Rome, Rome, Italy, ²UTHealth Houston, Houston, TX, ³BIDMC, Boston, MA, ⁴Division of Musculoskeletal and Dermatological Sciences, The University of Manchester, Manchester Academic Health Science Centre, Manchester, UK, Manchester, England, United Kingdom, ⁵UTHealth Houston Division of Rheumatology, Houston, TX, ⁶UT Health Houston Division of Rheumatology, Houston, TX, ⁷Division of Rheumatology, UTHealth Houston, Houston, Texas, USA, Houston, TX, ⁸UT Health Houston, Houston, TX
Background/Purpose: Cardiac manifestations significantly impact the prognosis of patients with systemic sclerosis (SSc), underscoring the need for early risk stratification. While gastrointestinal (GI) symptoms are…
Abstract Number: 0445 • ACR Convergence 2025
GLP-1 Receptor Agonists Reduce Mortality and Cardiovascular Events in Patients with Rheumatoid Arthritis
Giorgos Loizidis and Ross summer, Thomas Jefferson University, Philadelphia, PA
Background/Purpose: Obesity significantly increases cardiovascular morbidity and mortality in rheumatoid arthritis (RA), yet effective strategies for managing obesity-related risks in this population remain limited. Glucagon-like…
Abstract Number: 0581 • ACR Convergence 2025
Effects of Apremilast on Body Mass Index, Weight, and HbA1c as Cardiometabolic Outcomes in Patients With Early Oligoarticular Psoriatic Arthritis in the FOREMOST Study
Philip J. Mease¹, Álvaro González Cantero², Jennifer Soung³, April Armstrong⁴, Joseph F Merola⁵, Fabian Proft⁶, Laure Gossec⁷, Dafna D. Gladman⁸, Laura Coates⁹, Lichen Teng¹⁰, Jimena Vázquez¹¹, Cynthia Deignan¹² and Arthur Kavanaugh¹³, ¹Department of Rheumatology, Providence-Swedish Medical Center and University of Washington, Seattle, WA, ²Department of Dermatology, Ramón y Cajal University Hospital, Madrid, Spain, ³Southern California Dermatology, Inc, Santa Ana, CA, USA, Santa Ana, ⁴University of California Los Angeles, Los Angeles, ⁵Department of Dermatology and Department of Medicine, UT Southwestern Medical Center, Dallas, TX, ⁶Department of Gastroenterology, Infectiology and Rheumatology (including Nutrition Medicine), Charité – Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany, ⁷Sorbonne Université, Pitié Salpêtrière Hospital, Paris, France, ⁸Schroeder Arthritis Institute, Krembil Research Institute, Toronto Western Hospital, Division of Rheumatology, Toronto, ON, Canada, ⁹Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, England, United Kingdom, ¹⁰Amgen Inc., Thousand Oaks, ¹¹Amgen Inc., Thousand Oaks, CA, ¹²Amgen, Inc., Agoura Hills, CA, ¹³University of California, San Diego, School of Medicine, San Diego, CA
Background/Purpose: The prevalence of cardiometabolic diseases, including obesity and diabetes, is higher in patients with psoriatic arthritis (PsA) than those without PsA.1,2 Metabolic syndrome is…
Abstract Number: 2568 • ACR Convergence 2025
Cardiovascular Risk Prediction in Systemic Lupus Erythematosus: Comparing the PREVENT and SLECRISK Models
Youngmin Kim¹, Hongshu Guan², Emily Oakes¹, Katherine Zhong³, Misti Paudel⁴, May Choi⁵, Katherine Liao¹, Brittany Weber⁶ and Karen H. Costenbader⁷, ¹Brigham and Women's Hospital, Boston, MA, ²Brigham and Women's Hospital/ Harvard Medical School, Boston, ³Brigham and Women's Hospital, Short Hills, NJ, ⁴Brigham and Women's Hospital, Division of Rheumatology, Inflammation, and Immunity, Boston, MA, ⁵University of Calgary, Calgary, AB, Canada, ⁶Brigham and Women's Hospital, DEDHAM, MA, ⁷Harvard Medical School and Brigham and Women's Hospital, Boston, MA
Background/Purpose: Patients with systemic lupus erythematosus (SLE) have increased risk for atherosclerotic cardiovascular disease (CVD) events, often underrepresented in traditional risk models. We previously developed…
Abstract Number: 2146 • ACR Convergence 2025
Impact of a Clinical Pathway on Medication Use and Outcomes in Kawasaki Disease
Jonathan Yu¹, Matthew Elias¹, Deborah Whitney¹, Sanjeev Swami¹, Kaylie Shojaie¹, Caroline Burlingame¹, Isabel Armendi¹, Malki Peskin², Melissa Lerman¹, Jerri Miller¹, Jane Lavelle¹, Brandon Ku¹ and Jon Burnham³, ¹Children's Hospital of Philadelphia, Philadelphia, PA, ²Children's Hospital of Philadelphia, Bala Cynwyd, PA, ³Children's Hospital of Philadelphia, Bryn Mawr, PA
Background/Purpose: Kawasaki disease (KD) is an acute, systemic vasculitis which can lead to coronary artery (CA) aneurysms in young children. In 2018, we developed a…
Abstract Number: 1709 • ACR Convergence 2025
Association Between Social Risk Factors and Major Adverse Cardiovascular Events Among Individuals with Rheumatic Conditions
Leah Santacroce¹, Jeong Yee², Jing Cui³, Emily Oakes¹, Hongshu Guan⁴ and Karen H. Costenbader⁵, ¹Brigham and Women's Hospital, Boston, MA, ²Sungkyunkwan University, Suwon, MA, South Korea, ³Brigham Women's Hospital, Boston, MA, ⁴Brigham and Women's Hospital/ Harvard Medical School, Boston, ⁵Harvard Medical School and Brigham and Women's Hospital, Boston, MA
Background/Purpose: Individuals with rheumatic conditions are at an increased risk of experiencing cardiovascular events. Social risk factors contribute to disparities in comorbidities and adverse outcomes…
Abstract Number: 1333 • ACR Convergence 2025
Assessment of lipid abnormalities after initiation of a JAK inhibitor in rheumatoid arthritis in clinical practice
Salomé Abdellaoui¹, Omar Al Tabaa¹, Sophie Hecquet¹, Alice Combier¹, Sandrine Carves¹, Olivier Fogel², Yannick Allanore³ and Jérôme Avouac⁴, ¹Rheumatology department, Cochin Hospital, Paris, France, ²AP-HP, Paris, France, ³Université Paris Cité, Paris, France, ⁴Hôpital Cochin, AP-HP Centre - Université Paris Cité, Paris, France
Background/Purpose: rheumatoid arthritis (RA) is characterized by a lipid paradox induced by systemic inflammation. JAK inhibitors (JAKi) have been associated with a short-term increase in…
Abstract Number: 0669 • ACR Convergence 2025
Clinical and Laboratory Factors Associated With Biopsy-Confirmed Antimalarial-Induced Cardiomyopathy
Youngmin Kim¹, Norioscar Cabello², Robert Padera², Brittany Weber³ and Karen H. Costenbader⁴, ¹Brigham and Women's Hospital, Boston, MA, ²Brigham and Women's Hospital, Boston, ³Brigham and Women's Hospital, DEDHAM, MA, ⁴Harvard Medical School and Brigham and Women's Hospital, Boston, MA
Background/Purpose: Hydroxychloroquine (HCQ) is widely prescribed in rheumatology, particularly for systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA). Though generally safe, HCQ can cause rare…
Abstract Number: 0438 • ACR Convergence 2025
Exploring the Potential for Cardiorenal-Metabolic Therapies to Target Comorbidities in Early Rheumatoid Arthritis
Bindee Kuriya¹, Susan J. Bartlett², Marie-France Valois³, Janet Pope⁴, Carter Thorne⁵, Carol Hitchon⁶, Hugues Allard-Chamard⁷, Glen Hazlewood⁸, Gilles Boire⁹, Louis Bessette¹⁰ and Vivian Bykerk¹¹, ¹Mount Sinai Health, Toronto, Canada, ²McGill University, Beaconsfield, QC, Canada, ³McGill University, Pointe-Claire, QC, Canada, ⁴University of Western Ontario, London, ON, Canada, ⁵Centre of Arthritis Excellence, Newmarket, ON, Canada, ⁶University of Manitoba, Winnipeg, MB, Canada, ⁷Université de Sherbrooke, Sherbrooke, Canada, ⁸University of Calgary, Calgary, AB, Canada, ⁹Retired, Sherbrooke, QC, Canada, ¹⁰Centre de l'Ostéoporose et de Rhumatologie de Québec, Quebec, QC, Canada, ¹¹Hospital for Special Surgery, New York, NY
Background/Purpose: Cardiorenal-metabolic (CRM) therapies, such as SGLT-2 inhibitors and GLP-1 agonists, are medications that target interconnected pathways between cardiovascular, renal, and metabolic systems and may…
Abstract Number: 2567 • ACR Convergence 2025
Temporal Trends in Cardiometabolic Multimorbidity Risk in Rheumatoid Arthritis: A National, Matched Cohort Study
Tate Johnson¹, Joshua Baker², Punyasha Roul³, Grant Cannon⁴, Gary Kunkel⁵, Brian Sauer⁶, Ted Mikuls¹ and Bryant England¹, ¹University of Nebraska Medical Center, Omaha, NE, ²University of Pennsylvania, Philadelphia, PA, ³UNMC, Omaha, NE, ⁴University of Utah and Salt Lake City VA, Salt Lake City, UT, ⁵University of Utah and George E Wahlen VAMC, Salt Lake City, UT, ⁶Salt Lake City VA/University of Utah, Salt Lake City, UT
Background/Purpose: Multimorbidity, the presence of multiple chronic conditions, is over-represented in RA. A cardiometabolic multimorbidity (CMM) phenotype has emerged in the general population, but is…
Abstract Number: 2009 • ACR Convergence 2025
Value of New PREVENT Calculator in Detecting Cardiovascular Disease in Patients with Gout
Patrick Williamson¹, Rouhin Sen² and Angelo Gaffo³, ¹Tinsley Harrison Internal Medicine Residency, Department of Medicine, University of Alabama at Birmingham, Birmingham, ²University of Alabama at Birmingham, Department of Medicine, Division of Clinical Immunology & Rheumatology, Birmingham, ³Division of Rheumatology and Clinical Immunology, University of Alabama, Birmingham, AL, USA; Birmingham VA Medical Center, Birmingham, AL, USA, Birmingham, AL
Background/Purpose: Gout is associated with a 50% increased risk of cardiovascular disease (CVD).1 The current recommendation for evaluating CVD risk in gout is to use…
Abstract Number: 1658 • ACR Convergence 2025
Cardiovascular Disease Risk and Risk Calculator Performance in Rheumatoid Arthritis-Associated Interstitial Lung Disease
Omair Khan¹, Halie Frideres², Punyasha Roul³, Grant Cannon⁴, Gary Kunkel⁵, Brian Sauer⁶, Joshua Baker⁷, Ted Mikuls¹, Bryant England¹ and Tate Johnson¹, ¹University of Nebraska Medical Center, Omaha, NE, ²UNMC Department of Rheumatology, Omaha, NE, ³UNMC, Omaha, NE, ⁴University of Utah and Salt Lake City VA, Salt Lake City, UT, ⁵University of Utah and George E Wahlen VAMC, Salt Lake City, UT, ⁶Salt Lake City VA/University of Utah, Salt Lake City, UT, ⁷University of Pennsylvania, Philadelphia, PA
Background/Purpose: Existing cardiovascular disease (CVD) risk stratification strategies underperform in RA. Lung disease is an established CVD risk factor, and RA-interstitial lung disease (RA-ILD) clinically…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].